A striking conformity emerged among pharmaceutical companies, all targeting the same dangerous part of the virus despite the apparent business and safety contradictions. The discussion highlights the technical distinction of the new vaccine as a "pro drug," emphasizing the uniqueness of individual biology and the impossibility of achieving consistent therapeutic effects across a diverse population. A small group of experts questions the feasibility and safety of this approach, raising concerns about the implications of such mass compliance in drug development.
